Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanismnectin-4 modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-102 in Subjects with Advanced or Metastatic Solid Tumors That Express EphA2
This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors
A Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-101 in Subjects with Advanced or Metastatic Solid Tumors That Express Nectin-4
This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.
一项评价注射用SC-101在表达Nectin-4的晚期恶性实体肿瘤患者中的安全性、药代动力学特征和有效性的Ⅰ期临床研究
[Translation] A Phase I clinical study to evaluate the safety, pharmacokinetic characteristics and efficacy of SC-101 for injection in patients with advanced malignant solid tumors expressing nectin-4
评价注射用SC-101治疗晚期恶性实体瘤患者的安全性、药代动力学特征、免疫原性和有效性
[Translation] To evaluate the safety, pharmacokinetic characteristics, immunogenicity and efficacy of SC-101 for injection in the treatment of patients with advanced malignant solid tumors
100 Clinical Results associated with Tianjin Conjustar Biotechnology Co., Ltd.
0 Patents (Medical) associated with Tianjin Conjustar Biotechnology Co., Ltd.
100 Deals associated with Tianjin Conjustar Biotechnology Co., Ltd.
100 Translational Medicine associated with Tianjin Conjustar Biotechnology Co., Ltd.